Original Article
Subject Category: Immunology/Infection
Journal of Investigative Dermatology (2007) 127, 1673–1680; doi:10.1038/sj.jid.5700777; published online 22 March 2007
Imiquimod Enhances the Systemic Immunity Attained by Local Cryosurgery Destruction of Melanoma Lesions
Pedro Redondo1, Julio del Olmo1, Ascensión López-Diaz de Cerio2, Susana Inoges2, Miren Marquina1, Ignacio Melero3 and Maurizio Bendandi2
- 1Department of Dermatology, University Clinic of Navarra, Pamplona, Navarra, Spain
- 2Laboratory of Immunotherapy, Oncology Division, Center for Applied Medical Research, University of Navarra, Pamplona, Navarra, Spain
- 3Laboratory of Gene Therapy, Hepatology Division, Center for applied Medical Research, University of Navarra, Pamplona, Navarra, Spain
Correspondence: Dr Pedro Redondo, Department of Dermatology, University Clinic of Navarra, PO Box 4209, 31008 Pamplona, Navarra, Spain. E-mail: predondo@unav.es
Received 16 October 2006; Revised 20 December 2006; Accepted 3 January 2007; Published online 22 March 2007.
Abstract
Melanoma lesions can be frozen in vivo, resulting in necrotic death of malignant cells and in tumor antigen release suitable for cross-presentation by professional antigen-presenting cells. Imiquimod is a small molecule with adjuvant pro-inflammatory effects that can be topically delivered as a cream. Local cryosurgery of B16/ovalbumin (OVA)-derived subcutaneous tumor nodules leads to curative destruction of the lesions. If imiquimod is repeatedly applied on the cryo-treated lesion, a conspicuous, leukocyte-rich inflammatory infiltrate appears during the days following treatment. Mice treated by cryosurgery plus imiquimod rejected rechallenges of B16/OVA in 90% of the cases, whereas cryosurgery alone failed to prevent tumor grafting in 70% of the cases. The combination treatment of B16/OVA tumors was also able to protect 60% of the mice against outgrowth of a lethal dose of non-transfected B16 tumor cells. Addition of imiquimod to cryosurgery results in increases of the cellular immune response against tumor antigens as measured by in vitro IFN-
production and T-cell proliferation in response to OVA. The potent memory response is not only directed against the OVA epitope, but also toward a broader range of B16 antigens. Our data indicate that these combined treatments turn the treated tumor lesion into an autologous tumor vaccine, which is even able to cause vitiligo in several cases. These preclinical data and the simplicity of the procedures warrant the design of a pilot clinical trial.
Abbreviations:
DC, dendritic cell; OVA, ovalbumin; pDC, plasmacytoid DC; TLR, toll-like receptor
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo ? use of the human tyrosinase promoter with human enhancersCancer Gene Therapy Original Article
Death Receptor-Independent Apoptosis in Malignant Melanoma Induced by the Small-Molecule Immune Response Modifier ImiquimodJournal of Investigative Dermatology Original Article
Topical CpG Enhances the Response of Murine Malignant Melanoma to DacarbazineJournal of Investigative Dermatology Original Article
See all 5 matches for Research


